Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft- versus-Host Disease and Response to Steroid Treatment Sascha Dietrich,

Slides:

Advertisements

Similar presentations

Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell.

Advertisements

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation María.

How to Treat MDS without Stem Cell Transplantation

Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease Melanie N. Stauber,

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Gastrointestinal Acute Graft-versus-Host Disease in Children: Histology for Diagnosis, Mesenchymal Stromal Cells for Treatment, and Biomarkers for Prediction.

Predictive Value of Circulating Angiopoietin-2 for Endothelial Damage–Related Complications in Allogeneic Hematopoietic Stem Cell Transplantation Norihiro.

High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell.

CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease Sung-Eun Lee, Ji-Young Lim, Jae-Ho Yoon, Seung-Hwan Shin, Byung-Sik Cho, Ki-Seong.

Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease Florent Delbos, Walid Barhoumi, Ludovic Cabanne,

Sabina Kersting, Leo F. Verdonck

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation Albert C.

Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Plasma Biomarkers in Graft-versus-Host Disease: A New Era?

Chronic graft-versus-host disease

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Role of the Mycobiome in Human Acute Graft-versus-Host Disease

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review Filippo.

Helicobacter pylori Infection and Graft-versus-Host Disease

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Acute Gastrointestinal Graft-versus-Host Disease in Pediatric Patients: Serum Albumin on Day 5 from Initiation of Therapy Correlates with Nonrelapse Mortality.

Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning

Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease Divaya.

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Treatment of Severe Refractory Acute Graft-versus-Host Disease of the Gastrointestinal Tract with Campath-1H Alessandro Busca, Franco Locatelli, Elisabetta.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease Shigeo Fuji,

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts Kile Green, Kim Pearce, Rob.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory.

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus- Host Disease Prophylaxis Austin P. Huffman, Lee P. Richman, Lisa Crisalli,

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial

Mammen Chandy Biology of Blood and Marrow Transplantation

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Presentation transcript:

Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft- versus-Host Disease and Response to Steroid Treatment Sascha Dietrich, Christine S. Falk, Axel Benner, Suzan Karamustafa, Esther Hahn, Mindaugas Andrulis, Ute Hegenbart, Anthony D. Ho, Peter Dreger, Thomas Luft Biology of Blood and Marrow Transplantation Volume 19, Issue 1, Pages 22-27 (January 2013) DOI: 10.1016/j.bbmt.2012.09.018 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Median levels of endothelial serum parameters ANG2 (A), sTM (B), IL-8 (CXCL8) (C), and HGF (D) measured before allo-SCT and on days +50 and +100 after allo-SCT. Serum samples obtained posttransplantation were available for 331 patients, at day +50 after allo-SCT in 297 patients, and at day +100 after allo-SCT in 300 patients. ANG2 was elevated in steroid-refractory patients before allo-SCT compared with patients with sensitive grade III-IV GVHD (P < .03, refractory grade III-IV versus sensitive grade III-IV; P < .05, refractory grade III-IV versus sensitive grade I-II; Wilcoxon’s rank sum test), but did not differ compared with those with low-grade GVHD or no GVHD. No significant pretransplantation differences in the other parameters (IL-8, HGF, and sTM) were detected. On days +50 and +100, sTM, IL-8 (CXCL8), and HGF levels were significantly higher in patients with refractory grade III-IV GVHD compared with those in all other groups (P < .05). Biology of Blood and Marrow Transplantation 2013 19, 22-27DOI: (10.1016/j.bbmt.2012.09.018) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Cumulative incidence of NRM in patients with low ANG2 levels (<1000 pg/mL) and high ANG2 levels (>1000 pg/mL) measured before allo-SCT, calculated using Gray’s test. (A) All patients. (B) Patients with grade I-II GVHD. (C) Patients with grade III-IV GVHD. Biology of Blood and Marrow Transplantation 2013 19, 22-27DOI: (10.1016/j.bbmt.2012.09.018) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Supplemental Figure 1 Biology of Blood and Marrow Transplantation 2013 19, 22-27DOI: (10.1016/j.bbmt.2012.09.018) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions